Buprenorphine Uses, Dosage, Side Effects and Interactions
Butrans
Butrans was approved by the FDA in June 2010 as a skin patch. An FDA-approved generic with the same active ingredient is listed.
Belbuca
Belbuca was approved by the FDA in October 2015 as a buccal film. No generic is listed as buccal films, though generic buprenorphine is listed as injections, skin patches and sublingual tablets.
Sublocade
Sublocade was approved by the FDA in November 2017 as an injection. The FDA rates no generic as a substitute for it.
Buprenex
Buprenex is a buprenorphine brand from before 1982 that came as an injection. The FDA now lists it as discontinued; generic buprenorphine is still listed.
Brixadi
Brixadi was approved by the FDA in May 2023 as an injection. The FDA rates no generic as a substitute for it.
Buprenorphine is a partial opioid medicine used to treat opioid use disorder (opioid dependence) and to manage severe, persistent pain, depending on the product and form.
Quick links
Ask Anything About BuprenorphineType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Buprenorphine in Short
- Drug class Partial Opioid Agonist How the FDA classifies it
What it treatsBuprenorphine is used for two main purposes, and which one applies depends on the product. Opioid use disorder: Buprenorphine sublingual tablets (opioid dependence, preferred for induction), Sublocade and Brixadi (moderate to severe opioid use disorder) are used with counseling and psychosocial support.
- How you get it Prescription only Controlled substance, Schedule III
- Comes asSublingual tablet, skin patch, injection and buccal filmAvailable strengths
Sublingual tablet (under the tongue)
- 2 mg
- 4 mg
- 8 mg
- 12 mg
Skin patch (through the skin)
- 5 mcg/h
- 7.5 mcg/h
See forms and strengths+ 21 more strengthsShow fewer strengths
Skin patch (through the skin)
- 10 mcg/h
- 15 mcg/h
- 20 mcg/h
Injection (into a muscle, into a vein, under the skin)
- 8 mg/0.16 mL
- 16 mg/0.32 mL
- 24 mg/0.48 mL
- 32 mg/0.64 mL
- 64 mg/0.18 mL
- 96 mg/0.27 mL
- 100 mg
- 128 mg/0.36 mL
- 300 mg
Injection (into a muscle, into a vein, under the skin), amount in each mL
- 0.3 mg/mL
- 0.324 mg/mL
Buccal film (inside the cheek)
- 75 mcg
- 150 mcg
- 300 mcg
- 450 mcg
- 600 mcg
- 750 mcg
- 900 mcg
- The FDA’s strongest warningBoxed warning on some forms On the patch, the injection and the forms held in the cheek. Read the warnings for your exact product.
- What pharmacies pay
- Generic$0.30 to $0.56 a tablet
- Injections: no national price found
The pharmacy’s own cost, national average. Not your price See every price+ 3 more price detailsShow fewer price details
- Skin patches, generic: $22.81 to $56.76 each
- Skin patches, Butrans: $48.90 to $131.06 each
- Buccal films, Belbuca: $7.54 to $18.59 each
- Generic versionYes, FDA-approved Listed with the FDA, which does not mean every pharmacy stocks it
The Pharmacist’s Take
Buprenorphine is a partial opioid (it switches on the brain’s opioid receptors only partway), a leading first-choice medicine for opioid use disorder and an option for severe, persistent pain when other treatments fall short; it has been on the U.S. market since about 1981, and FDA-approved generics are listed. Most people tolerate it reasonably well, and the side effects they notice most are nausea, constipation and headache, plus itchy or red skin under a patch. Watch above all for slowed or shallow breathing, a boxed warning risk alongside addiction and fatal accidental exposure in children, and one that climbs sharply with alcohol or sedating drugs.
Key Takeaways From the HelloPharmacist Team
- Dissolve tablets whole under the tongue, wear each patch a full 7 days, and expect Sublocade or Brixadi as shots from your provider.
- Keep naloxone, the overdose-reversal medicine, at home, and call 911 if someone on buprenorphine is breathing slowly or hard to wake.
- Store every form locked up and out of children’s reach, because even one tablet, film or patch can kill a child.
- Keep heating pads, electric blankets, hot tubs and saunas off a patch, and report a fever, because heat pushes more drug in.
Patient Information Guide for Buprenorphine
What It’s Used For
Buprenorphine is used for opioid use disorder and for pain, depending on the product.
- Sublingual tablets: opioid dependence, preferred for induction, with counseling and support.
- Sublocade (subcutaneous): moderate to severe opioid use disorder.
- Brixadi (subcutaneous): moderate to severe opioid use disorder.
- Belbuca (buccal film): severe, persistent pain needing an opioid.
- Butrans and buprenorphine skin patches: severe, persistent pain needing an opioid.
- Buprenorphine hydrochloride injection: pain severe enough to need an opioid when other treatments are inadequate.
How It Works
Buprenorphine is a partial agonist at the mu-opioid receptor, so it activates the receptor only partly. It also blocks kappa-opioid receptors and acts on delta and ORL-1 (nociceptin) receptors. How much each action contributes to pain relief is unclear.
Drug Class
Drug Class
- Partial Opioid Agonist
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Partial Opioid Agonist
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Partial Opioid Agonists
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Buprenorphine in the FDA’s index.
From our Patient Information GuideBuprenorphine is a partial agonist at the mu-opioid receptor, so it activates the receptor only partly. It also blocks kappa-opioid receptors and acts on delta and ORL-1 (nociceptin) receptors. Read How Buprenorphine Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Buprenorphine in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Oripavine derivatives
- Drugs used in opioid dependence
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Dosing depends on the product, so follow your prescriber and the label.
- Sublingual tablets: once daily under the tongue, kept whole.
- Skin patch: worn for 7 days at a time.
- Belbuca: a film placed inside the cheek.
- Sublocade and Brixadi: injected under the skin by a healthcare provider only.
- Buprenorphine hydrochloride injection: given into a muscle or vein.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Buprenorphine Dissolved Under the Tongue
Opioid dependence
Adults dependent on heroin or other short-acting opioids · Induction Starting dose 2 to 4 mg
- First dose only when objective and clear signs of moderate opioid withdrawal appear, not less than 4 hours after last opioid use
- Initial day dosing may be given in 2 mg to 4 mg increments
- In one study 8 mg on Day 1 and 16 mg on Day 2
Adults dependent on methadone or other long-acting opioids · Induction First dose only when objective and clear signs of moderate opioid withdrawal appear, and generally not less than 24 hours after last long-acting opioid
Good to know
Withdrawal more likely with methadone doses above 30 mg
Adults · Maintenance Usual dose 16 mg once a day
Step by step
- Adjust in increments/decrements of 2 mg or 4 mg buprenorphine
- Recommended dose after induction 16 mg buprenorphine per day
- Generally in the range of 4 mg to 24 mg buprenorphine per day, single daily dose
- Dosages higher than 24 mg daily have not been investigated in randomized clinical trials
Adults with severe liver problems Consider reducing the starting and titration incremental dose by half
Good to know
Monitor for toxicity or overdose
Brixadi
Opioid use disorder
Adults not currently taking buprenorphine · First week Starting dose 16 mg Usual dose 24 mg once a week Highest dose 32 mg in the first week
Step by step
- Test dose of transmucosal buprenorphine 4 mg, then Brixadi (weekly) 16 mg
- Additional 8 mg within 3 days to reach 24 mg; if needed an additional 8 mg after at least 24 hours for a total weekly dose of 32 mg
Adults taking sublingual buprenorphine 6 mg or less daily Usual dose 8 mg once a week
- Brixadi (weekly) 8 mg
- Brixadi (monthly) --
Adults taking sublingual buprenorphine 8-10 mg daily Usual dose 16 mg once a week
Step by step
- Brixadi (weekly) 16 mg
- Brixadi (monthly) 64 mg
Adults taking sublingual buprenorphine 12-16 mg daily Usual dose 24 mg once a week
Step by step
- Brixadi (weekly) 24 mg
- Brixadi (monthly) 96 mg
Adults taking sublingual buprenorphine 18-24 mg daily Usual dose 32 mg once a week
Step by step
- Brixadi (weekly) 32 mg
- Brixadi (monthly) 128 mg
Adults switching from weekly to monthly Brixadi · 16 mg Usual dose 64 mg once a month
- Brixadi (monthly) 64 mg
Adults switching from weekly to monthly Brixadi · 24 mg Usual dose 96 mg once a month
- Brixadi (monthly) 96 mg
Adults switching from weekly to monthly Brixadi · 32 mg Usual dose 128 mg once a month
- Brixadi (monthly) 128 mg
Buprenorphine Injection
Pain
Adults and children over 12 years old Starting dose 0.3 mg every 6 hours as needed
Step by step
- 1 mL (0.3 mg buprenorphine) by deep intramuscular or slow (over at least 2 minutes) intravenous injection at up to 6-hour intervals, as needed
- May repeat once (up to 0.3 mg) 30 to 60 minutes after initial dose
- Single doses up to 0.6 mg I.M. only in adults not high risk
Good to know
High-risk patients: limit to minimum required
Children 2 to 12 years old 2-6 micrograms/kg of body weight every 4-6 hours
Good to know
No dose recommended below age two years; no repeat dose at 30-60 minutes
Sublocade
Opioid use disorder
Adults not already taking buprenorphine · Starting and maintenance Starting dose 300 mg Usual dose 100 mg once a month
Step by step
- Initial dose of 4 mg transmucosal buprenorphine
- Injection #1 300 mg
- Injection #2 300 mg (as early as 1 week and up to 1 month later)
- Then maintenance 100 mg monthly
Good to know
Maintenance 300 mg monthly may be considered if satisfactory response not shown
Opioid use disorder, transition from transmucosal buprenorphine 8 – 24 mg/day Starting dose 300 mg Usual dose 100 mg once a month
Step by step
- Injection #1 300 mg
- Injection #2 300 mg
- Maintenance 100 mg
Good to know
Those on 8 mg to 18 mg daily may receive 100 mg as second dose if symptoms controlled
Buprenorphine Skin Patch
Severe, ongoing pain
Adults taking 30 mg or less oral morphine equivalent daily · Starting dose Starting dose 5 mcg/hour patch for 7 days
- 5 mcg/hour patch, worn for 7 days
Adults taking 30 mg to 80 mg oral morphine equivalent daily · Starting dose Starting dose 10 mcg/hour patch for 7 days
- 10 mcg/hour patch, worn for 7 days
Good to Know for Every Dose
Wait a minimum of 3 weeks before using same site
Buprenorphine Dissolved in the Cheek
Severe, ongoing pain
Adults taking less than 30 mg oral MSE · Starting dose Starting dose 75 mcg once a day or every 12 hours
- Belbuca 75 mcg once daily or every 12 hours
Adults taking 30 mg to 89 mg oral MSE · Starting dose Starting dose 150 mcg every 12 hours
- Belbuca 150 mcg every 12 hours
Adults taking 90 mg to 160 mg oral MSE · Starting dose Starting dose 300 mcg every 12 hours
- Belbuca 300 mcg every 12 hours
Side Effects
Common side effects with the buprenorphine patch include:
Common side effects
- Nausea
- Headache
- Dizziness
- Constipation
- Sleepiness
- Vomiting
- Dry mouth
- Itching, redness or rash at the patch site (skin patch)
When to get medical help
- Slow or shallow breathing, extreme sleepiness, or trouble waking up: call 911 right away
- Suspected overdose, including accidental exposure in a child: get emergency help immediately
- Severe skin reaction at the patch site, such as burning, discharge or blisters: report it promptly
- Signs of an allergic reaction, such as swelling or trouble breathing
- Fainting or severe lightheadedness
- Pain that gets worse or becomes more sensitive while on the medicine
- Signs of serotonin syndrome if taken with other serotonergic drugs
- Withdrawal symptoms in a newborn if used for a long time in pregnancy
Warnings and Precautions
- Slowed breathing can be life-threatening, especially when starting or after a dose increase.
- Addiction, abuse and misuse can happen even at prescribed doses.
- Accidental exposure, especially in children, can be fatal.
- Alcohol and sedating drugs greatly raise the risk of coma and death.
- Heat or fever can raise drug levels from the patch.
- Long-term use in pregnancy can cause newborn withdrawal.
- Opioids can sometimes make pain worse (hyperalgesia).
Interactions
Several drugs can change how buprenorphine works or raise its risks.
- Alcohol, benzodiazepines, gabapentinoids and other sedatives: extreme sleepiness and slowed breathing.
- CYP3A4 inhibitors (ketoconazole, erythromycin, ritonavir, atazanavir): higher buprenorphine levels.
- CYP3A4 inducers (rifampin, carbamazepine, phenytoin, phenobarbital): lower levels and possible withdrawal.
- MAO inhibitors: Sublocade is not recommended within 14 days.
- Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol): risk of serotonin syndrome.
- Muscle relaxants: added breathing risk.
- Diuretics: may work less well.
Interactions Listed in the FDA-Approved Label
From the Buprenorphine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Benzodiazepines and other CNS depressants For example: alcoholWhat happensIncreases the risk of respiratory depression, profound sedation, coma, and death.What to doCessation is preferred in most cases; if concomitant use is warranted, strongly consider prescribing naloxone.
-
CYP3A4 inhibitors For example: ketoconazole, erythromycin, ritonavirWhat happensCan increase buprenorphine plasma concentration, resulting in increased or prolonged opioid effects.What to doMonitor for signs and symptoms of over-medication; it may be necessary to remove the depot.
-
CYP3A4 inducers For example: rifampin, carbamazepine, phenytoin, phenobarbitalWhat happensMay increase clearance, lowering buprenorphine levels, causing lack of efficacy or abstinence syndrome.What to doMonitor for withdrawal; transition to adjustable-dose buprenorphine if needed.
-
Antiretrovirals: NNRTIs (efavirenz, nevirapine, etravirine, delavirdine)What happensPharmacokinetic interactions shown with sublingual buprenorphine did not result in significant pharmacodynamic effects.What to doMonitor for increase or decrease in therapeutic effects.
-
Antiretrovirals: protease inhibitors (atazanavir, ritonavir)What happensAtazanavir with or without ritonavir elevated buprenorphine levels and increased sedation; nelfinavir, lopinavir/ritonavir, ritonavir had little effect.What to doMonitor for over-medication; it may be necessary to remove the depot.
-
Antiretrovirals: NRTIsWhat happensDo not appear to induce or inhibit the P450 pathway, so no interactions are expected.What to doNone
-
Serotonergic drugs (SSRIs, SNRIs, TCAs, triptans, tramadol, etc.)What happensConcomitant use with opioids has resulted in serotonin syndrome.What to doMonitor carefully for serotonin syndrome, especially at initiation and dose adjustment.
-
Monoamine oxidase inhibitors (MAOIs)What happensMay manifest as serotonin syndrome or opioid toxicity.What to doUse not recommended with MAOIs or within 14 days of stopping them.
-
Muscle relaxantsWhat happensBuprenorphine may enhance neuromuscular blocking action and increase respiratory depression.What to doMonitor for respiratory depression and decrease the muscle relaxant dose as necessary; strongly consider naloxone.
-
DiureticsWhat happensOpioids can reduce diuretic efficacy by inducing release of antidiuretic hormone.What to doMonitor for diminished diuresis and blood pressure effects; increase the diuretic dose as needed.
Read the label’s full interactions text
7 DRUG INTERACTIONS Table 3 includes clinically significant drug interactions with Buprenorphine Sublingual Tablets. Table 3. Clinically Significant Drug Interactions with Buprenorphine Sublingual Tablets Benzodiazepines or other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. Intervention: Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In some cases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or CNS depressant or decreasing to the lowest effective dose may be appropriate. Before co-prescribing benzodiazepines for anxiety or insomnia, ensure that patients are appropriately diagnosed and consider alternative medications and non-pharmacologic treatments. If concomitant use is warranted, strongly consider recommending or prescribing an opioid overdose reversal agent, as is recommended for all patients on buprenorphine treatment for opioid use disorder. Examples: Benzodiazepines and other sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol. Inhibitors of CYP3A4 Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of Buprenorphine Sublingual Tablets is achieved.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Not for people with significant breathing problems, a bowel blockage or an allergy to buprenorphine (patch labeling).
- Tell your prescriber about asthma or lung disease.
- Mention any history of substance misuse or mental illness.
- Severe liver problems may need a lower starting dose.
- Older adults need monitoring for sedation and slowed breathing.
- Discuss pregnancy; buprenorphine passes into breast milk.
Overdose
Overdose can cause slowed breathing, deep sleepiness progressing to coma, limp muscles, cold clammy skin and pinpoint pupils. Call 911 right away. For the patch, remove it immediately; monitoring for at least 24 hours may be needed. Naloxone may be less effective against buprenorphine, so emergency care is essential.
How Your Body Processes It
Each buprenorphine patch delivers medicine for 7 days, reaching steady levels by about day 3. Drug is usually detectable about 17 hours after application. Buprenorphine is processed mainly by the liver enzyme CYP3A4 and cleared through bile into stool and through urine. After a patch is removed, levels fall about 50% in 12 hours.
Storage
Store Buprenorphine Sublingual Tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Buprenorphine: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Buprenorphine — the kind of thing our pharmacy team would talk through with you at the counter.
What is buprenorphine used for?
How should I take it?
What side effects should I expect?
Can I drink alcohol or take sleep or anxiety medicines with it?
Can I use a heating pad over my patch?
Is it safe in pregnancy?
Is buprenorphine available over the counter?
Is buprenorphine a controlled substance?
When was buprenorphine first available?
Who makes buprenorphine?
What is the brand name of buprenorphine?
What is the generic name of Butrans?
What drug class is buprenorphine?
Is there a generic version of buprenorphine?
What strengths does buprenorphine come in?
How much does buprenorphine cost?
Is there a buprenorphine shortage?
Where can I read the buprenorphine prescribing information (package insert)?
Is buprenorphine gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Buprenorphine
Skip the scrolling. Ask in your own words and get an answer from Buprenorphine’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Buprenorphine’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Buprenorphine on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Buprenorphine Forms and Strengths (How It Comes)
Buprenorphine comes in 4 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Buprenorphine inactive ingredients by manufacturer.
Sublingual tablet
How this form is used
- Buprenorphine sublingual tablets are used for opioid dependence and are preferred for induction, along with counseling and support.
- Buprenorphine sublingual tablets are taken under the tongue as a single daily dose.
- Buprenorphine HCl sublingual tablets must be kept whole: don't cut, chew or swallow them.
- Buprenorphine sublingual tablets do not contain naloxone and are preferred only during induction.
Skin patch
How this form is used
- Butrans is used for severe, persistent pain that needs an opioid and can't be managed with other options.
- Buprenorphine transdermal system is used for severe, persistent pain; it is not for as-needed use.
- Butrans and buprenorphine transdermal system patches should be prescribed only by professionals experienced with extended-release opioids.
- Each buprenorphine transdermal system patch delivers medicine for 7 days.
- Avoid heating pads, electric blankets, saunas and hot tubs on the patch area.
Injection
How this form is used
- Sublocade is used for moderate to severe opioid use disorder, along with counseling and support.
- Brixadi is used for moderate to severe opioid use disorder, along with counseling and support.
- Buprenorphine hydrochloride injection is used for pain severe enough to need an opioid when other treatments are inadequate.
- Sublocade is prepared and given only by a healthcare provider, as an injection under the skin.
- Brixadi is given only by a healthcare provider, as a slow injection under the skin.
- Brixadi weekly and monthly are different formulations, and their doses can't be combined.
- Buprenorphine hydrochloride injection is given into a muscle or vein.
Show 5 more strengths Show fewer strengths
Buccal film
How this form is used
- Belbuca is used for severe, persistent pain that needs an opioid and can't be managed with other options, including immediate-release opioids.
- Belbuca is not for as-needed pain relief.
- Belbuca should be prescribed only by professionals experienced with extended-release opioids.
- Belbuca is used at the lowest effective dose for the shortest time.
- Breathing problems can occur at any time with Belbuca, especially at the start or after a dose increase.
Show 1 more strength Show fewer strengths
Buprenorphine on the U.S. Market: Products, Makers and Brands
How Buprenorphine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
32 companies list 107 Buprenorphine product records with the FDA, mostly as sublingual tablet, skin patch, injection; the earliest marketing or approval year on record is 1981. Brand names in the directory today include Butrans, Belbuca, Sublocade and 1 more; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (45) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Buprenorphine Is Used (Medicaid Data)
How many Buprenorphine prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Buprenorphine prescribed? Of the 1,682 medications we measure, Buprenorphine ranks #136 by Medicaid prescriptions — more than 92% of them.
Utilization by Buprenorphine product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
buprenorphine 8 MG Sublingual Tablet Most dispensed
8 of 85 listed NDCs had Medicaid claims. RxNorm 351265
1.5 ML buprenorphine 200 MG/ML Prefilled Syringe
1 of 3 listed NDCs had Medicaid claims. RxNorm 1996192
0.5 ML buprenorphine 200 MG/ML Prefilled Syringe
1 of 3 listed NDCs had Medicaid claims. RxNorm 1996184
buprenorphine 2 MG Sublingual Tablet
8 of 65 listed NDCs had Medicaid claims. RxNorm 351264
0.36 ML buprenorphine 356 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 2639043
0.27 ML buprenorphine 356 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 2639041
168 HR buprenorphine 0.01 MG/HR Transdermal System
5 of 11 listed NDCs had Medicaid claims. RxNorm 904870
168 HR buprenorphine 0.02 MG/HR Transdermal System
6 of 11 listed NDCs had Medicaid claims. RxNorm 904876
168 HR buprenorphine 0.015 MG/HR Transdermal System
5 of 11 listed NDCs had Medicaid claims. RxNorm 1432969
0.18 ML buprenorphine 356 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 2639036
168 HR buprenorphine 0.005 MG/HR Transdermal System
5 of 12 listed NDCs had Medicaid claims. RxNorm 904880
buprenorphine 0.3 MG Buccal Film
1 of 2 listed NDCs had Medicaid claims. RxNorm 1716065
0.48 ML buprenorphine 50 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 2639031
168 HR buprenorphine 0.0075 MG/HR Transdermal System
5 of 9 listed NDCs had Medicaid claims. RxNorm 1542997
0.64 ML buprenorphine 50 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 2639033
buprenorphine 0.45 MG Buccal Film
1 of 3 listed NDCs had Medicaid claims. RxNorm 1716069
buprenorphine 0.9 MG Buccal Film
1 of 2 listed NDCs had Medicaid claims. RxNorm 1716086
buprenorphine 0.15 MG Buccal Film
1 of 2 listed NDCs had Medicaid claims. RxNorm 1716057
buprenorphine 0.6 MG Buccal Film
1 of 2 listed NDCs had Medicaid claims. RxNorm 1716073
0.32 ML buprenorphine 50 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 2639029
0.16 ML buprenorphine 50 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 2639021
buprenorphine 0.75 MG Buccal Film
1 of 2 listed NDCs had Medicaid claims. RxNorm 1716081
buprenorphine 0.075 MG Buccal Film
1 of 2 listed NDCs had Medicaid claims. RxNorm 1716077
1 ML buprenorphine 0.3 MG/ML Injection
1 of 8 listed NDCs had Medicaid claims. RxNorm 238129
1 ML buprenorphine 0.3 MG/ML Cartridge
1 of 2 listed NDCs had Medicaid claims. RxNorm 1655032
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 60 of the 249 listed Buprenorphine NDCs had Medicaid claims.
Compare Buprenorphine Products
A representative set of FDA-listed product records for Buprenorphine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Buccal film | ||||
| 75 mcg | Buccal | BioDelivery Sciences International Inc | NDA | View NDC → |
| 150 mcg | Buccal | BioDelivery Sciences International Inc | NDA | View NDC → |
| 300 mcg | Buccal | BioDelivery Sciences International Inc | NDA | View NDC → |
| 450 mcg | Buccal | BioDelivery Sciences International Inc | NDA | View NDC → |
| 600 mcg | Buccal | BioDelivery Sciences International Inc | NDA | View NDC → |
| 750 mcg | Buccal | BioDelivery Sciences International Inc | NDA | View NDC → |
| 900 mcg | Buccal | BioDelivery Sciences International Inc | NDA | View NDC → |
| 💊Injection | ||||
| 8 mg/0.16 mL | Subcutaneous | Braeburn Inc. | NDA | View NDC → |
| 16 mg/0.32 mL | Subcutaneous | Braeburn Inc. | NDA | View NDC → |
| 24 mg/0.48 mL | Subcutaneous | Braeburn Inc. | NDA | View NDC → |
| 32 mg/0.64 mL | Subcutaneous | Braeburn Inc. | NDA | View NDC → |
| 64 mg/0.18 mL | Subcutaneous | Braeburn Inc. | NDA | View NDC → |
| 96 mg/0.27 mL | Subcutaneous | Braeburn Inc. | NDA | View NDC → |
| 128 mg/0.36 mL | Subcutaneous | Braeburn Inc. | NDA | View NDC → |
| 0.324 mg/mL | Intramuscular, Intravenous | Gland Pharma Limited | ANDA | View NDC → |
| 0.324 mg/mL | Intramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 0.3 mg/mL | Intramuscular, Intravenous | Hospira, Inc. | ANDA | View NDC → |
| 100 mg | Subcutaneous | Indivior Inc. | NDA | View NDC → |
| 300 mg | Subcutaneous | Indivior Inc. | NDA | View NDC → |
| 0.324 mg/mL | Intramuscular, Intravenous | Par Health USA, LLC | ANDA | View NDC → |
| 0.324 mg/mL | Intramuscular, Intravenous | Somerset Therapeutics, LLC | ANDA | View NDC → |
| 💊Skin patch | ||||
| BUPRENORPHINE 5 mcg/h | Transdermal | Alvogen Inc. | ANDA | View NDC → |
| BUPRENORPHINE 10 mcg/h | Transdermal | Alvogen Inc. | ANDA | View NDC → |
| BUPRENORPHINE 15 mcg/h | Transdermal | Alvogen Inc. | ANDA | View NDC → |
| BUPRENORPHINE 20 mcg/h | Transdermal | Alvogen Inc. | ANDA | View NDC → |
| BUPRENORPHINE 5 mcg/h | Transdermal | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| BUPRENORPHINE 7.5 mcg/h | Transdermal | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| BUPRENORPHINE 10 mcg/h | Transdermal | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| BUPRENORPHINE 15 mcg/h | Transdermal | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| BUPRENORPHINE 20 mcg/h | Transdermal | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| BUPRENORPHINE 5 mcg/h | Transdermal | Aveva Drug Delivery Systems Inc. | ANDA | View NDC → |
| BUPRENORPHINE 7.5 mcg/h | Transdermal | Aveva Drug Delivery Systems Inc. | ANDA | View NDC → |
| BUPRENORPHINE 10 mcg/h | Transdermal | Aveva Drug Delivery Systems Inc. | ANDA | View NDC → |
| BUPRENORPHINE 15 mcg/h | Transdermal | Aveva Drug Delivery Systems Inc. | ANDA | View NDC → |
| BUPRENORPHINE 20 mcg/h | Transdermal | Aveva Drug Delivery Systems Inc. | ANDA | View NDC → |
| BUPRENORPHINE 5 mcg/h | Transdermal | Ingenus Pharmaceuticals, Llc | ANDA | View NDC → |
| BUPRENORPHINE 7.5 mcg/h | Transdermal | Ingenus Pharmaceuticals, Llc | ANDA | View NDC → |
| BUPRENORPHINE 10 mcg/h | Transdermal | Ingenus Pharmaceuticals, Llc | ANDA | View NDC → |
| BUPRENORPHINE 15 mcg/h | Transdermal | Ingenus Pharmaceuticals, Llc | ANDA | View NDC → |
| BUPRENORPHINE 20 mcg/h | Transdermal | Ingenus Pharmaceuticals, Llc | ANDA | View NDC → |
| BUPRENORPHINE 5 mcg/h | Transdermal | Knoa Pharma LLC | NDA | View NDC → |
| BUPRENORPHINE 7.5 mcg/h | Transdermal | Knoa Pharma LLC | NDA | View NDC → |
| BUPRENORPHINE 10 mcg/h | Transdermal | Knoa Pharma LLC | NDA | View NDC → |
| BUPRENORPHINE 15 mcg/h | Transdermal | Knoa Pharma LLC | NDA | View NDC → |
| BUPRENORPHINE 20 mcg/h | Transdermal | Knoa Pharma LLC | NDA | View NDC → |
| BUPRENORPHINE 20 mcg/h | Transdermal | LTS Therapy Systems, LLC | ANDA | View NDC → |
| BUPRENORPHINE 5 mcg/h | Transdermal | Rhodes Pharmaceuticals LLC | NDA AUTHORIZED GENERIC | View NDC → |
| BUPRENORPHINE 7.5 mcg/h | Transdermal | Rhodes Pharmaceuticals LLC | NDA AUTHORIZED GENERIC | View NDC → |
| BUPRENORPHINE 10 mcg/h | Transdermal | Rhodes Pharmaceuticals LLC | NDA AUTHORIZED GENERIC | View NDC → |
| BUPRENORPHINE 15 mcg/h | Transdermal | Rhodes Pharmaceuticals LLC | NDA AUTHORIZED GENERIC | View NDC → |
| BUPRENORPHINE 20 mcg/h | Transdermal | Rhodes Pharmaceuticals LLC | NDA AUTHORIZED GENERIC | View NDC → |
| BUPRENORPHINE 5 mcg/h | Transdermal | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| BUPRENORPHINE 7.5 mcg/h | Transdermal | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| BUPRENORPHINE 10 mcg/h | Transdermal | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| BUPRENORPHINE 15 mcg/h | Transdermal | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| BUPRENORPHINE 20 mcg/h | Transdermal | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 💊Sublingual tablet | ||||
| 8 mg | Sublingual | A-S Medication Solutions × 2 listings | ANDA | View NDC → |
| 2 mg | Sublingual | Actavis Pharma, Inc. | ANDA | View NDC → |
| 8 mg | Sublingual | Actavis Pharma, Inc. | ANDA | View NDC → |
| 2 mg | Sublingual | Advagen Pharma Ltd | ANDA | View NDC → |
| 4 mg | Sublingual | Advagen Pharma Ltd | ANDA | View NDC → |
| 8 mg | Sublingual | Advagen Pharma Ltd | ANDA | View NDC → |
| 12 mg | Sublingual | Advagen Pharma Ltd | ANDA | View NDC → |
| 2 mg | Sublingual | American Health Packaging | ANDA | View NDC → |
| 8 mg | Sublingual | American Health Packaging | ANDA | View NDC → |
| 2 mg | Sublingual | AvPAK | ANDA | View NDC → |
| 8 mg | Sublingual | AvPAK | ANDA | View NDC → |
| 2 mg | Sublingual | Bryant Ranch Prepack × 3 listings | ANDA | View NDC → |
| 8 mg | Sublingual | Bryant Ranch Prepack × 4 listings | ANDA | View NDC → |
| 2 mg | Sublingual | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 8 mg | Sublingual | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 2 mg | Sublingual | Clinical Solutions Wholesale, LLC × 3 listings | ANDA | View NDC → |
| 8 mg | Sublingual | Clinical Solutions Wholesale, LLC × 3 listings | ANDA | View NDC → |
| 2 mg | Sublingual | Direct_Rx × 2 listings | ANDA | View NDC → |
| 8 mg | Sublingual | Direct_Rx | ANDA | View NDC → |
| 2 mg | Sublingual | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 8 mg | Sublingual | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 2 mg | Sublingual | Major Pharmaceuticals | ANDA | View NDC → |
| 8 mg | Sublingual | Major Pharmaceuticals | ANDA | View NDC → |
| 2 mg | Sublingual | PAI Holdings, LLC dba PAI Pharma | ANDA | View NDC → |
| 8 mg | Sublingual | PAI Holdings, LLC dba PAI Pharma | ANDA | View NDC → |
| 2 mg | Sublingual | Redpharm Drug | ANDA | View NDC → |
| 8 mg | Sublingual | Redpharm Drug | ANDA | View NDC → |
| 2 mg | Sublingual | Remedyrepack Inc. × 3 listings | ANDA | View NDC → |
| 8 mg | Sublingual | Remedyrepack Inc. × 2 listings | ANDA | View NDC → |
| 2 mg | Sublingual | Rhodes Pharmaceuticals LLC | ANDA | View NDC → |
| 8 mg | Sublingual | Rhodes Pharmaceuticals LLC | ANDA | View NDC → |
| 2 mg | Sublingual | SpecGx LLC | ANDA | View NDC → |
| 8 mg | Sublingual | SpecGx LLC | ANDA | View NDC → |
| 2 mg | Sublingual | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 8 mg | Sublingual | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 2 mg | Sublingual | Unit Dose Solutions, Inc. | ANDA | View NDC → |
| 8 mg | Sublingual | Unit Dose Solutions, Inc. | ANDA | View NDC → |
Showing 107 of 107 products — FDA National Drug Code Directory. See every product, package size and price: browse all 107 Buprenorphine NDCs →
Buprenorphine Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Buprenorphine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Buprenorphine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Buprenorphine FDA Approval History
How Buprenorphine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Buprenorphine Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list 7 Buprenorphine recalls since July 2021. Five of them are still ongoing or began in the last six months and are listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Buprenorphine Hydrochloride, Injection 0.3 mg/mL, Rx Only, 5 x 1 mL Single Dose Vials, Manufactured for: Endo USA, Malvern, PA, NDC 42023-179-05 Lots: Lot#:83912, Exp Date 10/2026 Lot#:84234, Exp Date 11/2026 Lot#:84990, Exp Date 11/2026 Lot#:85003, Exp Date 12/2026 Lot#:86443, Exp Date 01/2027 Lot#:89909, Exp Date 05/2027 FDA record D-0876-2026 →
- Buprenorphine Sublingual Tablets (C-III), 2 mg, 30 Tablets (3x10), Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC#: 60687-481-21, (Individual Dose NDC: 60687-481… Lots: Lot # 1030023, Exp Date: 06/30/2027. FDA record D-0840-2026 →
- Buprenorphine HCl, CIII, Injection, 0.3 mg/mL, 5 x 1 mL Single Dose Vials per Carton, Rx Only, For Intramuscular or Intravenous use, Manufactured for: Endo USA, Malvern, PA 19355, NDC 42023-179-05 Lots: Lot #: 82886, exp 09/30/2026; 89646, exp 05/31/2027 FDA record D-0596-2026 →
- Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05. Lots: Lot #: 84132, Exp 02/28/2027; 87693, Exp 03/31/2027 FDA record D-0527-2026 →
- Buprenorphine Hydrochloride Injection, 0.3 mg base/mL, 1 mL Single-dose Carpuject, Sterile Cartridge Unit with Luer Lock, For Intramuscular or Intravenous Use, Rx Only, Distributed by Hospira, Inc.,… Lots: Lot#: HJ3965; Exp 2024/09 Lot#: HJ8546; Exp 2024/10 FDA record D-0564-2024 →
- Buprenorphine Sublingual Tablets, 8 mg, 30 count-bottles, Rx only, Manufactured by: Sun Pharma, NDC 62756-460-83. Lots: Lot #: DND1515A, Exp 08/24 FDA record D-0869-2023 →
- Buprenorphine HCl, Injection, 0.3mg/mL, For Intramuscular or Intravenous Use, Rx Only, 1mL Single Dose Vial, (supplied in packages of 5 vials) Distributed by Par Pharmaceutical, Chestnut Ridge, NY 10… Lots: Lot No: 343716, Exp. Date: 11/2021; Lot No: 350565, Exp. Date: 07/2022; Lot No: 26921, Exp. Date: 07/2022; Lot No: 36227, Exp. Date: 02/2023 FDA record D-0087-2024 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Buprenorphine in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 9
- Strengths
- 31
- Forms in current FDA listings
- 7 of 9
RxCUI 1819 -
Dose form (SCDF) CartridgeIn current FDA listings
RxCUI 1655031Its strength (SCD)-
1 mL buprenorphine 0.3 mg/mL
RxCUI 1655032
-
1 mL buprenorphine 0.3 mg/mL
-
Dose form (SCDF) Drug ImplantNo current FDA listing
RxCUI 1797649 -
Dose form (SCDF) Injectable SolutionIn current FDA listings
RxCUI 379112Its strength (SCD)-
1.8 mg/mL
RxCUI 1594650
-
1.8 mg/mL
-
Dose form (SCDF) InjectionIn current FDA listings
RxCUI 1729358Its strength (SCD)-
1 mL buprenorphine 0.3 mg/mL
RxCUI 238129
-
1 mL buprenorphine 0.3 mg/mL
-
Dose form (SCDF) Prefilled SyringeIn current FDA listings
RxCUI 1996183Its 9 strengths (SCD)-
0.16 mL buprenorphine 50 mg/mL
RxCUI 2639021 -
0.18 mL buprenorphine 356 mg/mL
RxCUI 2639036 -
0.27 mL buprenorphine 356 mg/mL
RxCUI 2639041 -
0.32 mL buprenorphine 50 mg/mL
RxCUI 2639029 -
0.36 mL buprenorphine 356 mg/mL
RxCUI 2639043 -
0.48 mL buprenorphine 50 mg/mL
RxCUI 2639031 -
0.5 mL buprenorphine 200 mg/mL
RxCUI 1996184 -
0.64 mL buprenorphine 50 mg/mL
RxCUI 2639033 -
1.5 mL buprenorphine 200 mg/mL
RxCUI 1996192
-
0.16 mL buprenorphine 50 mg/mL
-
Dose form (SCDF) Topical SolutionNo current FDA listing
RxCUI 2599845Its strength (SCD)-
20 mg/mL
RxCUI 2599846
-
20 mg/mL
-
Dose form (SCDF) Transdermal SystemIn current FDA listings
RxCUI 1806212Its 5 strengths (SCD)-
0.005 mg/hr
168-hour
RxCUI 904880 -
0.0075 mg/hr
168-hour
RxCUI 1542997 -
0.01 mg/hr
168-hour
RxCUI 904870 -
0.015 mg/hr
168-hour
RxCUI 1432969 -
0.02 mg/hr
168-hour
RxCUI 904876
-
0.005 mg/hr
168-hour
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Buprenorphine Supply and Shortage Status
Whether Buprenorphine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Buprenorphine Costs Pharmacies (NADAC Benchmark)
What pharmacies pay to buy Buprenorphine: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.
No national price was found for Buprenorphine injections, so the prices below are for the sublingual tablets, skin patches and buccal films only.
How the Pharmacy Price Has Changed
Pick a form, the generic or the brand, and a strength to see how its price has changed since Nov 2023.
At this strength, Butrans costs pharmacies $48.90 each.
For the generic BUPRENORPHINE 5 mcg/h skin patch, pharmacies paid an average of $22.81 each as of Nov 18, 2026, up 3% from $22.15 a year earlier. At this strength, Butrans costs pharmacies $48.90 each.
- What pharmacies pay now
- $22.81
- each, as of Nov 18, 2026
- Last 4 weeks
- Down 5.3%
- from $24.09 on Oct 21, 2026
- Last 12 months
- Up 3%
- from $22.15 on Nov 19, 2025
- Lowest and highest since Nov 2023
- $19.02 to $37.97
- each
See the numbers, month by month
| Month | Pharmacy price |
|---|---|
| Nov 2026 | $22.81 |
| Oct 2026 | $24.09 |
| Sep 2026 | $23.45 |
| Aug 2026 | $23.82 |
| Jul 2026 | $22.92 |
| Jun 2026 | $23.97 |
| May 2026 | $22.80 |
| Apr 2026 | $22.38 |
| Mar 2026 | $20.83 |
| Feb 2026 | $20.93 |
| Jan 2026 | $20.89 |
| Dec 2025 | $22.58 |
| Nov 2025 | $22.15 |
| Oct 2025 | $22.15 |
| Sep 2025 | $21.25 |
| Aug 2025 | $21.45 |
| Jul 2025 | $21.52 |
| Jun 2025 | $21.29 |
| May 2025 | $21.91 |
| Apr 2025 | $20.97 |
| Mar 2025 | $21.39 |
| Feb 2025 | $20.08 |
| Jan 2025 | $20.81 |
| Dec 2024 | $20.74 |
| Nov 2024 | $21.61 |
| Oct 2024 | $21.72 |
| Sep 2024 | $23.32 |
| Aug 2024 | $22.20 |
| Jul 2024 | $19.32 |
| Jun 2024 | $24.96 |
| May 2024 | $19.02 |
| Apr 2024 | $21.87 |
| Mar 2024 | $26.35 |
| Feb 2024 | $26.82 |
| Jan 2024 | $29.50 |
| Dec 2023 | $32.00 |
| Nov 2023 | $37.97 |
See all 19 prices in a table
| Form | Strength | Version | What pharmacies pay | |
|---|---|---|---|---|
| Skin patch · Transdermal | BUPRENORPHINE 5 mcg/h | Generic | $22.81 each | NDC details & price history |
| Skin patch · Transdermal | BUPRENORPHINE 5 mcg/h | Butrans (brand) | $48.90 each | NDC details & price history |
| Skin patch · Transdermal | BUPRENORPHINE 7.5 mcg/h | Generic | $37.41 each | NDC details & price history |
| Skin patch · Transdermal | BUPRENORPHINE 7.5 mcg/h | Butrans (brand) | $68.74 each | NDC details & price history |
| Skin patch · Transdermal | BUPRENORPHINE 10 mcg/h | Generic | $32.54 each | NDC details & price history |
| Skin patch · Transdermal | BUPRENORPHINE 10 mcg/h | Butrans (brand) | $73.55 each | NDC details & price history |
| Skin patch · Transdermal | BUPRENORPHINE 15 mcg/h | Generic | $48.00 each | NDC details & price history |
| Skin patch · Transdermal | BUPRENORPHINE 15 mcg/h | Butrans (brand) | $124.60 each | NDC details & price history |
| Skin patch · Transdermal | BUPRENORPHINE 20 mcg/h | Generic | $56.76 each | NDC details & price history |
| Skin patch · Transdermal | BUPRENORPHINE 20 mcg/h | Butrans (brand) | $131.06 each | NDC details & price history |
| Buccal film · Buccal | 75 mcg | Belbuca (brand) | $7.54 each | NDC details & price history |
| Buccal film · Buccal | 150 mcg | Belbuca (brand) | $7.55 each | NDC details & price history |
| Buccal film · Buccal | 300 mcg | Belbuca (brand) | $11.86 each | NDC details & price history |
| Buccal film · Buccal | 450 mcg | Belbuca (brand) | $16.11 each | NDC details & price history |
| Buccal film · Buccal | 600 mcg | Belbuca (brand) | $17.19 each | NDC details & price history |
| Buccal film · Buccal | 750 mcg | Belbuca (brand) | $18.08 each | NDC details & price history |
| Buccal film · Buccal | 900 mcg | Belbuca (brand) | $18.59 each | NDC details & price history |
| Sublingual tablet · Sublingual | 2 mg | Generic | $0.296 per tablet | NDC details & price history |
| Sublingual tablet · Sublingual | 8 mg | Generic | $0.560 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.
Buprenorphine Brand Names
Buprenorphine has 5 brand names on record: Butrans, Belbuca, Sublocade, Buprenex and others. Butrans, Belbuca, Sublocade and Brixadi are in the FDA’s product directory today; Buprenex is not. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Buprenorphine: Manufacturers and Labelers
32 companies list Buprenorphine products with the FDA. By number of product records, the largest are BioDelivery Sciences International Inc, Braeburn Inc., Bryant Ranch Prepack. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
…and 8 more on the FDA NDC directory.
Sources for This Buprenorphine Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. SpecGx LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →